Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

China Oncology Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

Best Price Guarantee Length Publisher Published Date SKU
from $2,990 145 Pages Renub Research February, 2022 RNBR16974292
Best Price Guarantee
Price from $2,990
Length 145 Pages
Publisher Renub Research
Published Date February, 2022
SKU RNBR16974292

China Oncology Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

China Oncology Drugs Market is anticipated to reach US$ 35.24 Billion by 2027. Cancer is among China’s high-priority disease areas, with patients experiencing a significant health burden. Hence, the cancer drugs industry is the fastest-growing central therapeutic area in China’s pharmaceutical market. In particular, the increasingly challenging treatment of complex, severe cancerous diseases through drugs has generated unmet medical needs, leading to the promising market potential of the China Cancer Drugs Market.

Further, the acceleration of innovation within the oncology drugs industry in China is critical to progress in managing China’s oncology burden. Exceptionally outpacing the growth rate of new cancer cases in China, the oncology drug market in China demonstrates robust growth.

China Oncology Drugs Market Size was US$ 23.70 Billion in 2021

Chinese Drugs Industry has been shaping initiatives grounded in the local environment, assuring that patients receive enhanced treatment options that are accessible and equitable to all. Moreover, recent trends fuelling China’s progress in cancer drugs are innovation. A wave of new biotech’s focused on oncology and improved quality in oncology research is boosting China’s Cancer Drugs Market.

In addition, other key growth drivers for the industry in China include the aging trend of the Chinese population, rising healthcare expenditure, and improving the public medical insurance system. Therefore, driven by multiple factors, the number of new cases of cancer in China treated by drugs has constantly been increasing. According to Renub Research report, China Cancer Drug Industry is expanding at a CAGR of 6.8% during 2021-2027.

Targeted Therapy Is the Most Dominating Segment in China Oncology Drugs Market:

In our report, China Cancer Drug Market covers the cancer therapy market and the cancer drugs market. In terms of therapy, cancer treatment has gone through a long development process in history. Effective therapies include chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy.

In addition, cancer supportive care, which refers to the medical care that focuses on relieving the symptoms caused by cancer treatments to improve the quality of life, has also evolved with the development of various cancer treatment therapies. As per our analysis, By Therapy, Targeted Therapy is the most dominating segment in China Oncology Drug Market.

Lung Cancer Segment Occupies the Largest Oncology Drugs Market Share:

By Indication, our report covers Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, and Kidney Cancer existing in the market. In addition, China looks set to become a primary developer of cancer drugs for the diverse indications infusing regulatory changes to simplify and encourage drug development, which also opens the door for more significant investment by international pharmaceutical brands.

According to Indication, the lung oncology segment occupies the largest oncology drugs market share due to the vast geriatric population in China. Besides, the breast cancer segment is expected to experience the fastest growth due to technological developments in cancer diagnostics and a rise in awareness related to the early diagnosis of cancer.

Key Players:

The major players operating in the China Oncology Drugs Market include Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc. Companies have explored different development pathways to accelerate regulatory approval for faster patient access. Additionally, key players are increasingly entering into R&D partnerships with local Chinese companies to accelerate approval and bring treatment to patients. In addition, companies are also offering schemes to improve affordability to help patients get appropriate treatment.

The COVID-19 Pandemic Disrupted the China Oncology Drugs Market:

The COVID-19 pandemic has had widespread adverse collateral effects on China Cancer Drugs Market. Remarkably, China’s Oncology Drugs Industry was reliant on rapid testing and diagnosis and on timely and coordinated multimodal treatment, all of which had been impacted by the pandemic adversely. However, over time, the initial and enduring effects of the COVID-19 pandemic on the utilization of cancer drugs deteriorated.

Renub Research report titled “China Oncology Drugs Market, by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) and Hormonal Therapy), Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, Other Cancers), Drugs ( ESAs (Erythropoiesis Stimulating Agents), G-CSFs (Granulocyte-colony Stimulating Factors), Anti-emetics, Bisphosphonates, Opioids, NSAIDs & Others), Companies (Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc)” provides a complete analysis of China Oncology Drugs Market.

Therapy – Market have been covered from 4 viewpoints:

1. Chemotherapy
2. Targeted Therapy
3. Immunotherapy (Biologic Therapy)
4. Hormonal Therapy

Indication – Market have been covered from 10 viewpoints:

1. Blood Cancer
2. Breast Cancer
3. Gastrointestinal Cancer
4. Prostate Cancer
5. Lung Cancer
6. Skin Cancer
7. Ovarian Cancer
8. Cervical Cancer
9. Kidney Cancer
10. Other Cancers

Drugs – Market have been covered from 6 viewpoints:

1. ESAs (Erythropoiesis Stimulating Agents)
2. G-CSFs (Granulocyte-colony Stimulating Factors)
3. Anti-emetics
4. Bisphosphonates
5. Opioids
6. NSAIDs & Others

Company Insights:

• Overview
• Recent Development & Strategies
• Revenue Analysis

Company Analysis:

1. Bristol Myers Squibb
2. Merck
3. Eli Lilly
4. Sino BioPharma
5. F Hoffmann-La Roche AG
6. Johnson & Johnson
7. AbbVie Inc.
8. AstraZeneca plc


1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. China Cancer Drugs Market
6. Market Share – China Oncology Drugs Market
6.1 By Therapy
6.2 By Indication
6.3 By Drugs
7. Therapy– China Oncology Drugs Market
7.1 Chemotherapy
7.2 Targeted Therapy
7.3 Immunotherapy (Biologic Therapy)
7.4 Hormonal Therapy
8. Indication– China Oncology Drugs Market
8.1 Blood Cancer
8.2 Breast Cancer
8.3 Gastrointestinal Cancer
8.4 Prostate Cancer
8.5 Lung Cancer
8.6 Skin Cancer
8.7 Ovarian Cancer
8.8 Cervical Cancer
8.9 Kidney Cancer
8.11 Other Cancers
9. Drugs– China Oncology Drugs Market
9.1 ESAs (Erythropoiesis Stimulating Agents)
9.2 G-CSFs (Granulocyte-colony Stimulating Factors)
9.3 Anti-emetics
9.4 Bisphosphonates
9.5 Opioids
9.6 NSAIDs & Others
10. Porters Five Forces
10.1 Overview
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Degree of Competition
10.5 Threat of New Entrants
10.6 Threat of Substitutes
11. Company Analysis
11.1 Bristol Myers Squibb
11.1.1 Overview
11.1.2 Recent Development
11.1.3 Revenue Analysis
11.2 Merc
11.2.1 Overview
11.2.2 Recent Development
11.2.3 Revenue Analysis
11.3 Eli Lilly
11.3.1 Overview
11.3.2 Recent Development
11.3.3 Revenue Analysis
11.4 Sino BioPharma
11.4.1 Overvie
11.4.2 Recent Development
11.4.3 Revenue Analysis
11.5 F Hoffmann-La Roche A
11.5.1 Overview
11.5.2 Recent Development
11.5.3 Revenue Analysis
11.6 Johnson & Johnson
11.6.1 Overview
11.6.2 Recent Development
11.6.3 Revenue Analysis
11.7 AbbVie Inc.
11.7.1 Overview
11.7.2 Recent Development
11.7.3 Revenue Analysis
11.8 AstraZeneca plc
11.8.1 Overview
11.8.2 Recent Development
11.8.3 Revenue Analysis
List Of Figures:
Figure-01: China Cancer Drugs Market (Billion US$), 2018 – 2021
Figure-02: Forecast for – China Cancer Drugs Market (Billion US$), 2022 – 2027
Figure-03: Therapy – Chemotherapy Market (Billion US$), 2018 – 2021
Figure-04: Therapy – Forecast for Chemotherapy Market (Billion US$), 2022 – 2027
Figure-05: Therapy – Targeted Therapy Market (Billion US$), 2018 – 2021
Figure-06: Therapy – Forecast for Targeted Therapy Market (Billion US$), 2022 – 2027
Figure-07: Therapy – Immunotherapy (Biologic Therapy) Market (Billion US$), 2018 – 2021
Figure-08: Therapy – Forecast for Immunotherapy (Biologic Therapy) Market (Billion US$), 2022 – 2027
Figure-09: Therapy – Hormonal Therapy Market (Billion US$), 2018 – 2021
Figure-10: Therapy – Forecast for Hormonal Therapy Market (Billion US$), 2022 – 2027
Figure-11: Indication – Blood Cancer Market (Billion US$), 2018 – 2021
Figure-12: Indication – Forecast for Blood Cancer Market (Billion US$), 2022 – 2027
Figure-13: Indication – Breast Cancer Market (Billion US$), 2018 – 2021
Figure-14: Indication – Forecast for Breast Cancer Market (Billion US$), 2022 – 2027
Figure-15: Indication – Gastrointestinal Cancer Market (Billion US$), 2018 – 2021
Figure-16: Indication – Forecast for Gastrointestinal Cancer Market (Billion US$), 2022 – 2027
Figure-17: Indication – Prostate Cancer Market (Billion US$), 2018 – 2021
Figure-18: Indication – Forecast for Prostate Cancer Market (Billion US$), 2022 – 2027
Figure-19: Indication – Lung Cancer Market (Billion US$), 2018 – 2021
Figure-20: Indication – Forecast for Lung Cancer Market (Billion US$), 2022 – 2027
Figure-21: Indication – Skin Cancer Market (Billion US$), 2018 – 2021
Figure-22: Indication – Forecast for Skin Cancer Market (Billion US$), 2022 – 2027
Figure-23: Indication – Ovarian Cancer Market (Billion US$), 2018 – 2021
Figure-24: Indication – Forecast for Ovarian Cancer Market (Billion US$), 2022 – 2027
Figure-25: Indication – Cervical Cancer Market (Million US$), 2018 – 2021
Figure-26: Indication – Forecast for Cervical Cancer Market (Million US$), 2022 – 2027
Figure-27: Indication – Kidney Cancer Market (Billion US$), 2018 – 2021
Figure-28: Indication – Forecast for Kidney Cancer Market (Billion US$), 2022 – 2027
Figure-29: Indication – Other Cancers Market (Billion US$), 2018 – 2021
Figure-30: Indication – Forecast for Other Cancers Market (Billion US$), 2022 – 2027
Figure-31: Drugs – ESAs (Erythropoiesis Stimulating Agents) Market (Billion US$), 2018 – 2021
Figure-32: Drugs – Forecast for ESAs (Erythropoiesis Stimulating Agents) Market (Billion US$), 2022 – 2027
Figure-33: Drugs – G-CSFs (Granulocyte-colony Stimulating Factors) Market (Billion US$), 2018 – 2021
Figure-34: Drugs – Forecast for G-CSFs (Granulocyte-colony Stimulating Factors) Market (Billion US$), 2022 – 2027
Figure-35: Drugs – Anti-emetics (Billion US$), 2018 – 2021
Figure-36: Drugs – Forecast for Anti-emetics (Billion US$), 2022 – 2027
Figure-37: Drugs – Bisphosphonates (Billion US$), 2018 – 2021
Figure-38: Drugs – Forecast for Bisphosphonates (Billion US$), 2022 – 2027
Figure-39: Drugs – Opioids (Billion US$), 2018 – 2021
Figure-40: Drugs – Forecast for Opioids (Billion US$), 2022 – 2027
Figure-41: Drugs – NSAIDs & Others (Billion US$), 2018 – 2021
Figure-42: Drugs – Forecast for NSAIDs & Others (Billion US$), 2022 – 2027
Figure-43: Bristol Myers Squibb – Global Revenue (Billion US$), 2018 – 2021
Figure-44: Bristol Myers Squibb – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-45: Merck – Global Revenue (Billion US$), 2018 – 2021
Figure-46: Merck – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-47: Eli Lilly – Global Revenue (Billion US$), 2018 – 2021
Figure-48: Eli Lilly – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-49: Sino BioPharma – Global Revenue (Billion US$), 2018 – 2021
Figure-50: Sino BioPharma – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-51: F Hoffmann-La Roche AG – Global Revenue (Billion US$), 2018 – 2021
Figure-52: F Hoffmann-La Roche AG – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-53: Johnson & Johnson – Global Revenue (Billion US$), 2018 – 2021
Figure-54: Johnson & Johnson – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-55: AbbVie Inc. – Global Revenue (Billion US$), 2018 – 2021
Figure-56: AbbVie Inc. – Forecast for Global Revenue (Billion US$), 2022 – 2027
Figure-57: AstraZeneca plc – Global Revenue (Billion US$), 2018 – 2021
Figure-58: AstraZeneca plc – Forecast for Global Revenue (Billion US$), 2022 – 2027
List Of Tables:
Table-01: China Cancer Drugs Market Share by Therapy (Percent), 2018 – 2021
Table-02: Forecast for – China Cancer Drugs Market Share by Therapy (Percent), 2022 – 2027
Table-03: China Cancer Drugs Market Share by Indication (Percent), 2018 – 2021
Table-04: Forecast for – China Cancer Drugs Market Share by Indication (Percent), 2022 – 2027
Table-05: China Cancer Drugs Market Share by Drugs (Percent), 2018 – 2021
Table-06: Forecast for – China Cancer Drugs Market Share by Drugs (Percent), 2022 – 2027

$2,990
$3,990

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings